H

Hanall Biopharma Co Ltd
KRX:009420

Watchlist Manager
Hanall Biopharma Co Ltd
KRX:009420
Watchlist
Price: 27 800 KRW -0.18% Market Closed
Market Cap: 1.5T KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Hanall Biopharma Co Ltd

Wall Street analysts forecast Hanall Biopharma Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Hanall Biopharma Co Ltd is 47 685 KRW with a low forecast of 40 400 KRW and a high forecast of 68 250 KRW.

Lowest Forecast
Wall Street Target
40 400 KRW
45% Upside
Average Forecast
Wall Street Target
47 685 KRW
72% Upside
Highest Forecast
Wall Street Target
68 250 KRW
146% Upside
Lowest
Price Target
40 400 KRW
45% Upside
Average
Price Target
47 685 KRW
72% Upside
Highest
Price Target
68 250 KRW
146% Upside
Hanall Biopharma Co Ltd Competitors:
Price Targets
I
IMP
Imexpharm Corp
8% Upside
C
214370
Caregen Co Ltd
56% Upside
TERN
Terns Pharmaceuticals Inc
596% Upside
G
512
Grand Pharmaceutical Group Ltd
17% Upside
I
IMP
Imexpharm Corp
8% Upside
C
214370
Caregen Co Ltd
56% Upside
TERN
Terns Pharmaceuticals Inc
596% Upside
G
512
Grand Pharmaceutical Group Ltd
17% Upside
A
ABBOTINDIA
Abbott India Ltd
14% Upside
4569
Kyorin Holdings Inc
3% Upside
S
688506
Sichuan Biokin Pharmaceutical Co Ltd
12% Upside

Revenue
Forecast

Revenue Estimate
Hanall Biopharma Co Ltd

For the last 8 years the compound annual growth rate for Hanall Biopharma Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 13%.

7%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Hanall Biopharma Co Ltd

For the last 8 years the compound annual growth rate for Hanall Biopharma Co Ltd's operating income is -3%. The projected CAGR for the next 3 years is 354%.

-3%
Past Growth
354%
Estimated Growth
Estimates Accuracy
-53%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Hanall Biopharma Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Hanall Biopharma Co Ltd's stock price target?
Price Target
47 685 KRW

According to Wall Street analysts, the average 1-year price target for Hanall Biopharma Co Ltd is 47 685 KRW with a low forecast of 40 400 KRW and a high forecast of 68 250 KRW.

What is Hanall Biopharma Co Ltd's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Hanall Biopharma Co Ltd's revenue is 7%. The projected CAGR for the next 3 years is 13%.

What is Hanall Biopharma Co Ltd's Operating Income forecast?
Projected CAGR
354%

For the last 8 years the compound annual growth rate for Hanall Biopharma Co Ltd's operating income is -3%. The projected CAGR for the next 3 years is 354%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.